Megan Seyboth
Associate Director, Revenue Management
Expertise:
Megan has more than nine years of experience in the life sciences industry, specializing in Government Pricing (GP). She lead’s EVERSANA’s GP team and has a large range of experience in all areas related to GP calculations and reporting including but not limited enrollment into the Government Programs, calculations for AMP, BP, ASP, and NFAMP, and FSS Contracting including contract solicitations, contract modifications, and Public Law. She has worked with small, mid-size, and large pharmaceutical companies with both branded and generic products to understand industry best practices.
Articles by Megan Seyboth
Understanding the Role of AI in Government Pricing Compliance: New Risks and New Advantages
In the last few years, AI has evolved from a pipe dream into a world of possibilities and now has transitioned into a catalyst for change. AI will revolutionize how we monitor, document, and analyze information which in turn will change how we approach Government Pricing compliance. But while manufacturers are using AI for compliance […]
The Most-Favored-Nation Model, One Year Later: Where Do Globe, Guard, and Generous Stand Today?
A year ago, the debate surrounding the Most-Favored-Nation (MFN) model centered on a fundamental question: would international reference pricing create a more sustainable global benchmark, or introduce new risks across pharmaceutical markets? At the time, concerns focused on market disruption, access inequities, and the challenge of comparing fundamentally different healthcare systems. Today, those concerns remain […]
The Evolution of the 340B Rebate Model: Maintaining Patient Access while Minimizing Duplicate Discounts
The 340B program has struggled with implementing effective oversight of the covered entities since the program was established in 1992. Diversion and duplicate discounts are the primary issues that manufacturers face. Diversion typically happens when a 340B drug is dispensed to a non-340B patient and duplicate discounts typically happen when a product receives a 340B […]